Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the highest quintile among peers.
AlphaCentric LifeSci Healthcare A LYFAX
- NAV / 1-Day Return 12.32 / −1.12 %
- Total Assets 91.3 Mil
-
Adj. Expense Ratio
1.650%
- Expense Ratio 1.650%
- Distribution Fee Level High
- Share Class Type Front Load
- Category Health
- Investment Style Small Growth
- Min. Initial Investment 2,500
- Status Open
- TTM Yield —
- Turnover 142%
USD | NAV as of May 17, 2024 | 1-Day Return as of May 17, 2024, 10:17 PM GMT+0
Morningstar’s Analysis LYFAX
Will LYFAX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 35.6
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
First American Treasury Obligs X | 11.31 | 11.8 Mil | Cash and Equivalents |
Galapagos NV ADR | 4.09 | 4.3 Mil | Healthcare |
BioCryst Pharmaceuticals Inc | 3.88 | 4.0 Mil | Healthcare |
Pacira BioSciences Inc | 3.80 | 4.0 Mil | Healthcare |
United Therapeutics Corp | 3.80 | 4.0 Mil | Healthcare |
Harmony Biosciences Holdings Inc Ordinary Shares | 3.78 | 3.9 Mil | Healthcare |
Embecta Corp | 3.63 | 3.8 Mil | Healthcare |
Immunogen Inc | 3.63 | 3.8 Mil | Healthcare |
Coherus BioSciences Inc | 3.19 | 3.3 Mil | Healthcare |
Walgreens Boots Alliance Inc | 3.01 | 3.1 Mil | Healthcare |